Literature DB >> 19157609

Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT.

Eugenio Vanetti1, Alessandro Clivio, Giorgia Nicolini, Antonella Fogliata, Sarbani Ghosh-Laskar, Jai Prakash Agarwal, Ritu Raj Upreti, Ashwini Budrukkar, Vedang Murthy, Deepak Dattatray Deshpande, Shyam Kishore Shrivastava, Ketayun Ardeshir Dinshaw, Luca Cozzi.   

Abstract

PURPOSE: A planning study was performed to evaluate the performance of volumetric modulated arc radiotherapy on head and neck cancer patients. Conventional fixed field IMRT was used as a benchmark. METHODS AND MATERIALS: CT datasets of 29 patients with squamous cell carcinoma of the oro-pharynx, hypo-pharynx and larynx were included. Plans for fixed beam IMRT, single (RA1) and double (RA2) modulated arcs with the RapidArc technique were optimised. Dose prescription was set to 66 Gy to the primary tumour (at 2.2 Gy/fraction), 60 Gy to intermediate-risk nodes and 54 Gy to low-risk nodal levels. The planning objectives for PTV were minimum dose >95%, and maximum dose <107%. Maximum dose to spinal cord was limited to 46 Gy, maximum to brain stem to 50 Gy. For parotids, mean dose <26 Gy (or median <30 Gy) was assumed as the objective. The MU and delivery time were scored to measure expected treatment efficiency.
RESULTS: Target coverage and homogeneity results improved with RA2 plans compared to both RA1 and IMRT. All the techniques fulfilled the objectives on maximum dose, while small deviations were observed on minimum dose for PTV. The conformity index (CI(95%)) was 1.7+/-0.2 for all the three techniques. RA2 allowed a reduction of D(2%) to spinal cord of approximately 3 Gy compared to IMRT (RA1 D(2%) increased it of approximately 1 Gy). On brain stem, D(2%) was reduced from 12 Gy (RA1 vs. IMRT) to 13.5 Gy (RA2 vs. IMRT). The mean dose to ipsi-lateral parotids was reduced from 40 Gy (IMRT) to 36.2 Gy (RA1) and 34.4 Gy (RA2). The mean dose to the contra-lateral gland ranged from 32.6 Gy (IMRT) to 30.9 Gy (RA1) and 28.2 Gy (RA2).
CONCLUSION: RapidArc was investigated for head and neck cancer. RA1 and RA2 showed some improvements in organs at risk and healthy tissue sparing, while only RA2 offered improved target coverage with respect to conventional IMRT.

Entities:  

Mesh:

Year:  2009        PMID: 19157609     DOI: 10.1016/j.radonc.2008.12.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  130 in total

1.  Comparative analysis of SmartArc-based dual arc volumetric-modulated arc radiotherapy (VMAT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Hui-Min Ting; Su-Hua Lo; Yu-Wen Wang; Chiu-Ching Tuan; Fu-Min Fang; Te-Jen Su
Journal:  J Appl Clin Med Phys       Date:  2011-11-15       Impact factor: 2.102

Review 2.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

3.  Effect of photon-beam energy on VMAT and IMRT treatment plan quality and dosimetric accuracy for advanced prostate cancer.

Authors:  Marlies Pasler; Dietmar Georg; Holger Wirtz; Johannes Lutterbach
Journal:  Strahlenther Onkol       Date:  2011-11-29       Impact factor: 3.621

4.  Long-term follow-up results of simultaneous integrated or late course accelerated boost with external beam radiotherapy to vaginal cuff for high risk cervical cancer patients after radical hysterectomy.

Authors:  Xin Wang; Yaqin Zhao; Yali Shen; Pei Shu; Zhiping Li; Sen Bai; Feng Xu
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

5.  New possibilities for volumetric-modulated arc therapy using the Agility™ 160-leaf multileaf collimator.

Authors:  Nadine Blümer; Christian Scherf; Janett Köhn; Eugen Kara; Britta Loutfi-Krauß; Detlef Imhoff; Claus Rödel; Ulla Ramm; Jörg Licher
Journal:  Strahlenther Onkol       Date:  2014-07-25       Impact factor: 3.621

6.  Commissioning and first clinical application of mARC treatment.

Authors:  Yvonne Dzierma; Frank G Nuesken; Stephanie Kremp; Jan Palm; Norbert P Licht; Christian Rübe
Journal:  Strahlenther Onkol       Date:  2014-04-29       Impact factor: 3.621

7.  A Kindler syndrome-associated squamous cell carcinoma treated with radiotherapy.

Authors:  Ademar Caldeira; William Correia Trinca; Thais Pires Flores; Andrea Barleze Costa; Claudio de Sá Brito; Karen Loureiro Weigert; Maryana Schwartzhaupt Matos; Carmela Nicolini; Fernando Mariano Obst
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-10

8.  Real-time dynamic MLC tracking for inversely optimized arc radiotherapy.

Authors:  Marianne Falk; Per Munck af Rosenschöld; Paul Keall; Herbert Cattell; Byung Chul Cho; Per Poulsen; Sergey Povzner; Amit Sawant; Jens Zimmerman; Stine Korreman
Journal:  Radiother Oncol       Date:  2010-01-19       Impact factor: 6.280

9.  Neo-adjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience.

Authors:  Antonella Richetti; Antonella Fogliata; Alessandro Clivio; Giorgia Nicolini; Gianfranco Pesce; Emanuela Salati; Eugenio Vanetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2010-02-19       Impact factor: 3.481

10.  Simultaneous integrated boost radiotherapy for bilateral breast: a treatment planning and dosimetric comparison for volumetric modulated arc and fixed field intensity modulated therapy.

Authors:  Giorgia Nicolini; Alessandro Clivio; Antonella Fogliata; Eugenio Vanetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2009-07-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.